- EUR23M Series A Financing to Advance Lead Novel Llama-derived Antibody into Clinical Trials
- Technology Platform with Potential to Generate Robust Antiviral Therapies
- Founded by VIB, UCB Ventures and Fund+
Belgium, July 28th, 2020: ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices. ExeVir Bio has been established by Belgian partners combining world class science, antibody engineering, manufacturing, blue-chip venture capital investment and Flemish Government financing, which have joined forces in a unique collaboration to boost the development of new therapies to combat Covid-19.